{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:32:33Z","timestamp":1789612353244,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbcan.2026.189643","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:50:21Z","timestamp":1783356621000},"page":"189643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision targeting in biliary tract cancer therapy: A geographical, target, and efficacy analysis of clinical trials"],"prefix":"10.1016","volume":"1881","author":[{"given":"Fengfeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189643_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1384314","article-title":"Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the global burden of disease study 2019","volume":"11","author":"Su","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.bbcan.2026.189643_bb0010","first-page":"30","article-title":"An introduction to clinical trial design","volume":"32","author":"Schultz","year":"2019","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.bbcan.2026.189643_bb0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 trial investigators, cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189643_bb0020","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0025","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189643_bb0030","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Advanced biliary Cancer working group, second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911363","article-title":"Challenges and future trends of hepatocellular carcinoma immunotherapy","volume":"23","author":"Rizzo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189643_bb0040","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s12072-025-10799-2","article-title":"Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets","volume":"19","author":"Zhu","year":"2025","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bbcan.2026.189643_bb0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.21873\/invivo.11798","article-title":"Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis","volume":"34","author":"Rizzo","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.bbcan.2026.189643_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12935-025-03965-x","article-title":"The role of GPD2 and glycolysis-related genes in cholangiocarcinoma: insights into prognostic biomarkers and tumor-immune interactions","volume":"25","author":"Zhao","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2026.189643_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810869","article-title":"IDH inhibitors and immunotherapy for biliary tract cancer: a marriage of convenience?","volume":"23","author":"Brandi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189643_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189643_bb0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/17512433.2025.2590695","article-title":"Immunotherapy in biliary tract cancer: effective but not enough?","volume":"18","author":"Rizzo","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0075","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115432","article-title":"Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers","volume":"222","author":"Smolenschi","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189643_bb0085","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","article-title":"EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189643_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189643_bb0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","article-title":"Overview of current targeted therapy in gallbladder cancer","volume":"5","author":"Song","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189643_bb0100","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189643_bb0105","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189643_bb0110","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma","volume":"72","author":"O'Dell","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189643_bb0115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.21873\/cgp.20492","article-title":"KRAS mutations in cholangiocarcinoma: prevalence, prognostic value, and KRAS G12\/G13 detection in cell-free DNA","volume":"22","author":"Thongyoo","year":"2025","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.bbcan.2026.189643_bb0120","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00432-016-2254-9","article-title":"A let-7 microRNA binding site polymorphism in the KRAS 3\u2032UTR is associated with increased risk and reduced survival for gallbladder cancer in north indian population","volume":"142","author":"Kazmi","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0125","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12885-021-07792-x","article-title":"Clinically significant genomic alterations in the chinese and western patients with intrahepatic cholangiocarcinoma","volume":"21","author":"Xu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189643_bb0145","doi-asserted-by":"crossref","first-page":"e1565","DOI":"10.1093\/oncolo\/oyae154","article-title":"Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study","volume":"29","author":"Jing","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189643_bb0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2018.36.4_suppl.500","article-title":"Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0155","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0160","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2\u2013expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00262-024-03841-z","article-title":"Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.bbcan.2026.189643_bb0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma","volume":"9","author":"Lin","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.bbcan.2026.189643_bb0175","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2023.41.16_suppl.3029","volume":"41","author":"Ma","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0180","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189643_bb0185","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2024.42.16_suppl.3037","article-title":"Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: preliminary results from a phase 1 study","volume":"42","author":"Yu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/hbsn-24-463","article-title":"Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis","volume":"15","author":"Zheng","year":"2026","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.bbcan.2026.189643_bb0195","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.2018.36.4_suppl.478","article-title":"Downstaging of unresectable intrahepatic or hilar cholangiocellular carcinoma by selective intra-arterial floxuridine and systemic cisplatin and gemcitabine. A dose finding single center phase IIa study","volume":"36","author":"Pietge","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12072-014-9583-z","article-title":"Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma","volume":"9","author":"Yashima","year":"2015","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bbcan.2026.189643_bb0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1148\/radiol.2016160572","article-title":"Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma","volume":"283","author":"Wang","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.bbcan.2026.189643_bb0210","doi-asserted-by":"crossref","first-page":"15562","DOI":"10.1200\/jco.2008.26.15_suppl.15562","article-title":"Hepatic arterial infusion chemotherapy (HAI) with oxaliplatin (O), 5-fluorouracil (5FU), and folinic acid (FA) in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC): a phase II study","volume":"26","author":"Nicolaou","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2701","article-title":"First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors","volume":"40","author":"Pant","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0220","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/mt.2011.269","article-title":"Phase I trial of \u201cbi-shRNAi(furin)\/GMCSF DNA\/autologous tumor cell\u201d vaccine (FANG) in advanced cancer","volume":"20","author":"Senzer","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.bbcan.2026.189643_bb0225","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.2017.35.7_suppl.110","article-title":"Long-term follow-up of DNA engineered bi-shRNA furin GMCSF plasmid\/autologous tumor induced immune response in patients with advanced solid tumors (phase I trial)","volume":"35","author":"Nemunaitis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0230","doi-asserted-by":"crossref","first-page":"23961","DOI":"10.1038\/s41598-024-75102-z","article-title":"Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma","volume":"14","author":"Lin","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189643_bb0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12957-025-03882-3","article-title":"Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma","volume":"23","author":"Wang","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111642","article-title":"Lenvatinib combined with PD-1 inhibitor plus gemox chemotherapy versus plus HAIC for advanced biliary tract cancer","volume":"129","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0245","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s10620-013-2624-y","article-title":"Hepatic arterial infusion with oxaliplatin and 5-FU\/folinic acid for advanced biliary tract cancer: a phase II study","volume":"58","author":"Sinn","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbcan.2026.189643_bb0250","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/1751-2980.13127","article-title":"Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma","volume":"23","author":"Zhang","year":"2022","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.bbcan.2026.189643_bb0255","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0260","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine, clin. Cancer res","volume":"17","author":"Cheever","year":"2011","journal-title":"Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189643_bb0265","first-page":"3575","article-title":"MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer","volume":"25","author":"Yamamoto","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bbcan.2026.189643_bb0270","first-page":"955","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2008","journal-title":"Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189643_bb0275","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4161\/hv.23844","article-title":"Current status of immunotherapy for the treatment of biliary tract cancer","volume":"9","author":"Takahashi","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bbcan.2026.189643_bb0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0285","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189643_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"McNeely","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2026.189643_bb0300","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189643_bb0305","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/PPO.0000000000000556","article-title":"Development of next-generation poly(ADP-ribose) polymerase 1\u2013selective inhibitors","volume":"27","author":"Ngoi","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.bbcan.2026.189643_bb0310","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.3390\/cimb46110783","article-title":"Pharmacological and biological targeting of FGFR1 in cancer","volume":"46","author":"Fan","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189643_bb0320","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/j.bbcan.2026.189643_bb0325","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.cell.2026.03.001","article-title":"Hallmarks of liver cancer: therapeutic implications","volume":"189","author":"Llovet","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189643_bb0330","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.3390\/cancers13225671","article-title":"Molecular targets and emerging therapies for advanced gallbladder cancer","volume":"13","author":"Canale","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189643_bb0335","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11684-025-1144-4","article-title":"Precision medicine for advanced biliary tract cancer in China: current status and future perspectives","volume":"19","author":"Huang","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.bbcan.2026.189643_bb0340","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2584667","article-title":"Research progress on immune checkpoint inhibitors in intrahepatic cholangiocarcinoma","volume":"57","author":"Yin","year":"2025","journal-title":"Ann. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2026.189643_bb0345","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.3816\/CLC.2006.s.012","article-title":"Non-rash skin toxicities associated with novel targeted therapies","volume":"8","author":"Lacouture","year":"2006","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189643_bb0350","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"ENGOT-OV16\/NOVA investigators, niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189643_bb0355","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"Maitland","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2026.189643_bb0360","doi-asserted-by":"crossref","unstructured":"H.M. Said, C.T. Supuran, C. Hageman, A. Staab, B. Polat, A. Katzer, A. Scozzafava, J. Anacker, M. Flentje, D. Vordermark, Modulation of carbonic anhydrase 9 (CA9) in human brain cancer, Curr. Pharm. Des. 16 (n.d.) 3288\u20133299. doi:https:\/\/doi.org\/10.2174\/138161210793429788.","DOI":"10.2174\/138161210793429788"},{"key":"10.1016\/j.bbcan.2026.189643_bb0365","first-page":"862","article-title":"CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma","volume":"8","author":"Gu","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0370","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s13402-024-01022-9","article-title":"Targeting CA9 restricts pancreatic cancer progression through pH regulation and ROS production","volume":"47","author":"Yang","year":"2024","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0375","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00345-010-0570-2","article-title":"A clinical phase I\/II trial with the monoclonal antibody cG250 (RENCAREX\u00ae) and interferon-alpha-2a in metastatic renal cell carcinoma patients","volume":"29","author":"Siebels","year":"2011","journal-title":"World J. Urol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0380","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-21-4498","article-title":"FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189643_bb0385","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1093\/emboj\/17.19.5627","article-title":"The kinase Eg2 is a component of the Xenopus oocyte progesterone-activated signaling pathway","volume":"17","author":"Andr\u00e9sson","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2026.189643_bb0390","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1073\/pnas.202606599","article-title":"Identification of phosphorylated residues that affect the activity of the mitotic kinase aurora-a","volume":"99","author":"Littlepage","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2026.189643_bb0395","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/14728222.2014.956085","article-title":"Aurora kinase a inhibitors: promising agents in antitumoral therapy","volume":"18","author":"Malumbres","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbcan.2026.189643_bb0400","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/1078-0432.CCR-22-2036","article-title":"FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement","volume":"29","author":"Patel","year":"2023","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.bbcan.2026.189643_bb0405","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0410","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0415","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2026.189643_bb0420","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:35:11Z","timestamp":1785072911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0304419X26001150"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189643","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision targeting in biliary tract cancer therapy: A geographical, target, and efficacy analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189643"}}